[go: up one dir, main page]

JP2001524116A - 5ht1a、5ht1bおよび5ht1d受容体アンタゴニスト活性を合わせ持つインドール誘導体 - Google Patents

5ht1a、5ht1bおよび5ht1d受容体アンタゴニスト活性を合わせ持つインドール誘導体

Info

Publication number
JP2001524116A
JP2001524116A JP54766098A JP54766098A JP2001524116A JP 2001524116 A JP2001524116 A JP 2001524116A JP 54766098 A JP54766098 A JP 54766098A JP 54766098 A JP54766098 A JP 54766098A JP 2001524116 A JP2001524116 A JP 2001524116A
Authority
JP
Japan
Prior art keywords
indole
dihydro
methylpiperazin
chloro
bromo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP54766098A
Other languages
English (en)
Japanese (ja)
Inventor
ギャスター,ララミー・メアリー
ラミ,ハーシャド・カンティラル
ワイマン,ポール・エイドリアン
Original Assignee
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9707829.9A external-priority patent/GB9707829D0/en
Priority claimed from GBGB9801882.3A external-priority patent/GB9801882D0/en
Application filed by スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー filed Critical スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー
Publication of JP2001524116A publication Critical patent/JP2001524116A/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP54766098A 1997-04-18 1998-04-14 5ht1a、5ht1bおよび5ht1d受容体アンタゴニスト活性を合わせ持つインドール誘導体 Pending JP2001524116A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9707829.9A GB9707829D0 (en) 1997-04-18 1997-04-18 Novel compounds
GB9801882.3 1998-01-29
GBGB9801882.3A GB9801882D0 (en) 1998-01-29 1998-01-29 Novel compounds
GB9707829.9 1998-01-29
PCT/EP1998/002262 WO1998050358A1 (en) 1997-04-18 1998-04-14 Indole derivatives having combined 5ht1a, 5ht1b and 5ht1d receptor antagonist activity

Publications (1)

Publication Number Publication Date
JP2001524116A true JP2001524116A (ja) 2001-11-27

Family

ID=26311401

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54766098A Pending JP2001524116A (ja) 1997-04-18 1998-04-14 5ht1a、5ht1bおよび5ht1d受容体アンタゴニスト活性を合わせ持つインドール誘導体

Country Status (17)

Country Link
EP (1) EP0975593A1 (es)
JP (1) JP2001524116A (es)
KR (1) KR20010006487A (es)
CN (1) CN1260781A (es)
AR (1) AR013076A1 (es)
AU (1) AU732863B2 (es)
BR (1) BR9809092A (es)
CA (1) CA2288662A1 (es)
CO (1) CO4950608A1 (es)
HU (1) HUP0001123A3 (es)
IL (1) IL132409A0 (es)
NO (1) NO995065D0 (es)
NZ (1) NZ500252A (es)
PL (1) PL336317A1 (es)
TR (1) TR199902590T2 (es)
TW (1) TW509687B (es)
WO (1) WO1998050358A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526723A (ja) * 2002-02-15 2005-09-08 グラクソ グループ リミテッド バニロイド受容体モジュレーター
JP2017101008A (ja) * 2015-12-04 2017-06-08 東ソー株式会社 ルチジン化合物の精製方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725931D0 (en) * 1997-12-05 1998-02-04 Smithkline Beecham Plc Novel compounds
AU753360B2 (en) 1998-07-31 2002-10-17 Nippon Soda Co., Ltd. Phenylazole compounds, process for producing the same and drugs for hyperlipemia
GB9827882D0 (en) * 1998-12-17 1999-02-10 Smithkline Beecham Plc Novel compounds
UA62015C2 (en) * 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
JP2003505369A (ja) * 1999-07-15 2003-02-12 エヌピーエス アレリックス コーポレーション 偏頭痛を治療するための複素環式化合物
IL148818A0 (en) 1999-09-25 2002-09-12 Smithkline Beecham Plc Piperazine derivatives as 5-ht1b
DE60017446T2 (de) * 1999-11-05 2006-03-02 Smithkline Beecham P.L.C., Brentford Isochinolin- und Chinazolinderivate mit kombinierter 5-HT1A-, 5-HT1B- und 5-HT1D- Rezeptoraffinität
GB9926303D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
DE10051981A1 (de) 2000-10-20 2002-05-02 Bayer Ag Substituierte Phenyluracile
GB0106419D0 (en) 2001-03-15 2001-05-02 Smithkline Beecham Plc Novel compounds
GB0106586D0 (en) * 2001-03-16 2001-05-09 Smithkline Beecham Plc Novel compounds
DE60218037T2 (de) * 2001-06-07 2007-08-23 F. Hoffmann-La Roche Ag Neue indolderivate mit affinität zum 5-ht6-rezeptor
KR100636475B1 (ko) 2002-05-13 2006-10-18 에프. 호프만-라 로슈 아게 5-ht6 조절제로서 벤족사진 유도체 및 이의 용도
JP4527730B2 (ja) 2003-12-09 2010-08-18 エフ.ホフマン−ラ ロシュ アーゲー ベンゾオキサジン誘導体及びその使用
MX2010006046A (es) * 2007-12-13 2010-06-23 Amgen Inc Moduladores de gamma secretasa.
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
CN102924330A (zh) * 2012-09-03 2013-02-13 华东理工大学 一种规模化制备5-氨基-1-萘腈的方法
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CN103467374A (zh) * 2013-08-30 2013-12-25 江苏弘和药物研发有限公司 一种8-溴-4-羧基喹啉的合成方法
PL3083616T3 (pl) 2013-12-20 2021-12-06 Astex Therapeutics Limited Bicykliczne związki heterocykliczne i ich zastosowania w terapii
CN115197099A (zh) * 2022-05-30 2022-10-18 安徽昊帆生物有限公司 N-Boc-1,4-苯二胺的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119920D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
PT533268E (pt) * 1991-09-18 2002-02-28 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d
JPH09501171A (ja) * 1993-08-06 1997-02-04 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5ht1d受容体アンタゴニストとしてのアミド誘導体
JPH09504004A (ja) * 1993-08-20 1997-04-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5ht1dレセプター拮抗薬用アミドおよび尿素誘導体
DE69417427T2 (de) * 1993-09-03 1999-11-25 Smithkline Beecham P.L.C., Brentford Indol- und indolin-derivate als 5ht1d rezeptor antagonisten

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526723A (ja) * 2002-02-15 2005-09-08 グラクソ グループ リミテッド バニロイド受容体モジュレーター
JP2017101008A (ja) * 2015-12-04 2017-06-08 東ソー株式会社 ルチジン化合物の精製方法

Also Published As

Publication number Publication date
WO1998050358A1 (en) 1998-11-12
NO995065L (no) 1999-10-15
CO4950608A1 (es) 2000-09-01
EP0975593A1 (en) 2000-02-02
AU7431098A (en) 1998-11-27
AR013076A1 (es) 2000-12-13
KR20010006487A (ko) 2001-01-26
CN1260781A (zh) 2000-07-19
NO995065D0 (no) 1999-10-15
BR9809092A (pt) 2002-01-22
TW509687B (en) 2002-11-11
HUP0001123A2 (hu) 2001-04-28
IL132409A0 (en) 2001-03-19
AU732863B2 (en) 2001-05-03
PL336317A1 (en) 2000-06-19
CA2288662A1 (en) 1998-11-12
HUP0001123A3 (en) 2002-04-29
TR199902590T2 (xx) 2000-06-21
NZ500252A (en) 2001-07-27

Similar Documents

Publication Publication Date Title
JP2001524116A (ja) 5ht1a、5ht1bおよび5ht1d受容体アンタゴニスト活性を合わせ持つインドール誘導体
US20230233560A1 (en) Modulators of cystic fibrosis transmembrane conductance regulator
JP5031565B2 (ja) イソインドール化合物および代謝共役型グルタミン酸受容体増強剤としてのそれらの使用
JP2001526643A (ja) 5ht1a、5ht1bおよび5ht1d受容体アンタゴニスト活性を合わせ持つ化合物を含む二環式アリールまたは二環式複素環
CZ20021038A3 (cs) Piperazinové deriváty jako antagonisté 5-HT1B
JPH04253976A (ja) 新規インドール誘導体
EP2631229B1 (en) P2x4 receptor antagonist
JP2005527463A (ja) Cns疾患を治療するための5−ht6受容体アフィニティーを有する3−アリールスルホニル−7−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン
JP2002535331A (ja) 新規血管形成阻害薬
JPH07504429A (ja) 5HT↓1cアンタゴニストとしてのインドール誘導体
KR20030090694A (ko) 5-ht6 수용체의 길항제로서의 n-(2-아릴에틸)벤질아민
JP2009298819A (ja) スルホンアミド誘導体類と、その製造方法及び医薬としての応用
BRPI0707028A2 (pt) método para alcaçar um efeito em um paciente, composto e composição farmacêutica
TW200922580A (en) Quinoline derivatives
TW200922932A (en) Heterocyclic compound and pharmaceutical composition thereof
JP3165181B2 (ja) 新規の3−アリールインドールおよび3−アリールインダゾール誘導体
JP2002519348A (ja) 5−ht1fアゴニスト
JPH10500960A (ja) 5ht1d−アンタゴニスト活性を有するアミド誘導体
JPH08507067A (ja) Hiv逆転写酵素阻害剤
JPH04235164A (ja) 3−アリールカルボニル−1−アミノアルキル−1h−インドール含有抗緑内障組成物
JP5927071B2 (ja) Parp阻害活性を有する新規化合物
JP2001512727A (ja) 5ht−1受容体のリガンドとしてのニ環式化合物
CA3201443A1 (en) Tetrahydroquinoline derivative and medicinal use thereof
JP3012338B2 (ja) アリールおよびヘテロアリールアルコキシナフタレン誘導体
CN101406469B (zh) Gal3受体拮抗剂在治疗抑郁和/或焦虑中的应用及在这种方法中有用的化合物